SOST Human

Sclerostin Human Recombinant
Cat. No.
BT19531
Source
Escherichia Coli.
Synonyms
Sclerostin, SOST, CDD, VBCH.
Appearance
Filtered White lyophilized (freeze-dried) powder.
Purity
Greater than 90.0% as determined by SDS-PAGE.
Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

SOST Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain (a.a 24-213) containing 200 amino acids including a 10 a.a N-terminal His tag. The total molecular mass is 22.8kDa (calculated).

Product Specs

Introduction
Sclerostin (SOST), a secreted glycoprotein belonging to the DAN family of BMP antagonists, plays a crucial role in bone growth regulation. Characterized by a C-terminal cysteine knot-like (CTCK) domain, it inhibits bone formation, effectively acting as a negative regulator. SOST exhibits widespread expression at low levels, with heightened levels observed in bone, cartilage, kidney, liver, bone marrow, and primary osteoblasts differentiated for 21 days. Genetic defects in the SOST gene are linked to sclerosteosis and bone dysplasia.
Description
Recombinant human SOST, produced in E. coli, is a single, non-glycosylated polypeptide chain encompassing amino acids 24-213. This chain consists of 200 amino acids, including a 10 a.a N-terminal His tag, resulting in a calculated total molecular mass of 22.8 kDa.
Physical Appearance
White powder, lyophilized after filtration.
Formulation
SOST, after filtration through a 0.4 μm filter, is lyophilized from a 0.5 mg/ml solution in 0.03 M Acetate buffer with a pH of 4.0.
Solubility
To prepare a working stock solution of approximately 0.5 mg/ml, it is recommended to reconstitute the lyophilized pellet by adding 0.1 M Acetate buffer with a pH of 4.0. Allow for complete dissolution. For conversion to a higher pH value, intensive dilution with an appropriate buffer to a concentration of 10 μg/ml is recommended. The solubility of this antigen is limited at higher concentrations. Note: SOST is not sterile. Before use in cell culture, ensure the product is filtered through an appropriate sterile filter.
Stability
Lyophilized protein should be stored at -20°C. After reconstitution, aliquot the product to prevent repeated cycles of freezing and thawing. Reconstituted protein demonstrates stability at 4°C for a limited period and shows no changes after two weeks at this temperature.
Purity
Purity is determined to be greater than 90.0% as assessed by SDS-PAGE.
Synonyms
Sclerostin, SOST, CDD, VBCH.
Source
Escherichia Coli.
Amino Acid Sequence
MKHHHHHHASQGWQAFKNDA TEIIPELGEY PEPPPELENN KTMNRAENGG RPPHHPFETK DVSEYSCREL HFTRYVTDGP CRSAKPVTEL VCSGQCGPAR LLPNAIGRGK WWRPSGPDFR CIPDRYRAQR VQLLCPGGEA PRARKVRLVA SCKCKRLTRF HNQSELKDFG TEAARPQKGR KPRPRARSAK ANQAELENAY.

Product Science Overview

Discovery and Function

The SOST gene was initially identified as the gene responsible for two sclerosing bone dysplasias: sclerosteosis and van Buchem disease . Sclerostin is a member of the Dan family of glycoproteins, which are characterized by a cysteine-knot motif . It negatively regulates canonical Wnt signaling pathways by binding to low-density lipoprotein receptor-related protein (LRP) 5/6, thereby suppressing osteoblast differentiation and function .

Mechanism of Action

Sclerostin’s primary function is to inhibit the Wnt signaling pathway, which is crucial for bone formation . By binding to LRP5/6, sclerostin prevents the activation of Wnt signaling, thereby inhibiting osteoblast activity and bone formation . This regulation is essential for maintaining bone homeostasis and preventing excessive bone formation .

Clinical Relevance

The inhibition of sclerostin has been explored as a therapeutic strategy for treating osteoporosis Romosozumab, a specific anti-sclerostin antibody, has been developed to inhibit sclerostin-LRP5/6 interactions, thereby activating Wnt signaling and promoting bone formation . Clinical studies have demonstrated the efficacy of romosozumab in increasing bone mineral density and reducing osteoporotic fractures .

Recombinant Sclerostin

Recombinant human sclerostin is produced using recombinant DNA technology, which involves inserting the SOST gene into a suitable expression system to produce the protein in large quantities . This recombinant form is used in various research and clinical applications to study the protein’s function and develop therapeutic interventions .

Recent Developments

Recent advancements in the study of sclerostin include the development of second-generation immunoassays for measuring circulating sclerostin levels . These assays aim to overcome methodological obstacles and provide more accurate measurements of sclerostin levels in clinical settings . Additionally, the three-dimensional structure of human sclerostin has been generated using the AlphaFold Protein Structure Database, providing insights into its molecular interactions and functional properties .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.